Physician profile
Arbi Ohanian
NPI 1982894606
$6,805.16
in general payments reported to CMS, 2019-2025
53 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $300 · 2021: $651 · 2022: $779 · 2023: $969 · 2024: $1,431 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,055.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,331.98 | 2021-2025 | |
| Ucb, INC. | $494.72 | 2020-2025 | Fintepla, Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $376.85 | 2019-2025 | |
| Abbott Laboratories | $364.85 | 2019-2025 | Amplatzer Piccolo, Amplatzer, Infinity |
| Eisai INC. | $336.61 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $312.33 | 2021-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $256.23 | 2020-2024 | Ingrezza |
| Lundbeck LLC | $242.86 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $223.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $207.83 | 2019-2025 | Ocrevus Zunovo |
| Acorda Therapeutics, INC | $202.99 | 2022-2024 | Ampyra, Inbrija |
| Allergan, INC. | $182.19 | 2019-2021 | |
| Pfizer INC. | $176.95 | 2023-2025 | |
| Lilly USA, LLC | $174.67 | 2022-2025 | Kisunla, Amyvid |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 |
Show all 51 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arbi Ohanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.